Open Access. Powered by Scholars. Published by Universities.®

Medical Pharmacology Commons™

Open Access. Powered by Scholars. Published by Universities.®

2023

Discipline
Institution
Keyword
Publication
Publication Type

Articles 61 - 61 of 61

Full-Text Articles in Medical Pharmacology

Modulation Of Tlr4/Nf-Κb, Nrf2/Ho-1 And Pi3k/Akt Signaling By Cilostazol Mitigates Lipopolysaccharide-Induced Septic Acute Kidney Injury, Ahmed F. Mohamed Dr., Helmy Said Dr, Hala F. Zaki, Marwa M. Safar Prof. Dr. Jan 2023

Modulation Of Tlr4/Nf-Κb, Nrf2/Ho-1 And Pi3k/Akt Signaling By Cilostazol Mitigates Lipopolysaccharide-Induced Septic Acute Kidney Injury, Ahmed F. Mohamed Dr., Helmy Said Dr, Hala F. Zaki, Marwa M. Safar Prof. Dr.

Pharmacy

Aim: Cilostazol was investigated as a protective agent against lipopolysaccharide (LPS)-associated acute kidney damage in mice. Methods: Cilostazol (50 mg/kg/day; p.o.) administered for 7 consecutive days before a single LPS dose (2 mg/kg; i.p.). Results: Cilostazol hampered serum creatinine, cystatin C, and renal kidney injury molecule-1 and neutrophil gelatinase associated lipocalin; repressed toll-like receptor 4 and MyD88 transcription, as well as nuclear factor-kappa B p65, interleukin-1b, and malondialdehyde content; and boosted Nrf2 mRNA expression, hemeoxygenase-1 activity, and reduced glutathione content. This was synchronous with an upregulation of p-phosphoinositide 3-kinase and p-Akt expressions. Conclusion: Collectively, cilostazol prevented LPS renal injury, which …